Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Shares Up 6% – Still a Buy?

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF)’s stock price shot up 6% on Tuesday . The stock traded as high as $3.00 and last traded at $3.00. 500 shares traded hands during trading, a decline of 72% from the average session volume of 1,800 shares. The stock had previously closed at $2.83.

Hansa Biopharma AB (publ) Trading Up 6.0 %

The stock’s 50-day moving average is $3.31 and its 200 day moving average is $3.07.

Hansa Biopharma AB (publ) Company Profile

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test.